Navigation Links
Human Pheromone Sciences, Inc. - Shareholder Update
Date:10/27/2008

tructures

here in this country and in foreign markets.

Not only has our Company benefited financially from our agreements with

these world-class companies, our association with them has confirmed

the viability of our technology, an imperative for a small

technology-based business to generate interest of others in the longer

term.

-- While our historical business model has been validated by these

relationships, we are still dependent upon the internal timetable of

these licensees for the generation of revenues for our Company.

However, there are other viable and fast growing channels in which

consumer products are sold, including electronic media, and

direct-to-consumer companies, that may provide a more consistent flow

of revenues to our Company. During this year, your management has been

working to introduce our technology to several companies who are in

leaders in these fields. We hope to be able to provide more specifics

about these efforts shortly.

-- Technology - our heritage, our future; another focus of our Company.

During 2008, we have spent significant amounts of time, but not a lot

of money, in the development of new compounds. You will be hearing

more about the positive results of these efforts in the next two weeks.

-- Merger and Acquisition Opportunities. We feel strongly that our

current technology and new research and development initiatives can

continue to attract world-class partners. We have also undertaken a

program to seek mergers and/or other types of partnerships that can

enhance shareholder value - our ultimate goal.

Unlike many companies whose share price has dropped radically this year,

who have no historic operations, an un-tested business plan and tens of

millions of shares outstanding, our Compa
'/>"/>

SOURCE Human Pheromone Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. The human brain minimizes energy expenditure and integrates gravity in to the action plan
2. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
3. Humanitarian Offers $75 Million for Single Dose Sterilization of Cats and Dogs
4. Pioneer(R) Surgical Technology Announces First Human Implants of New nanOss(TM)-Cervical Fusion Device
5. Complete Genomics Launches, Becomes Worlds First Large-Scale Human Genome Sequencing Company
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at JMP Securities Conference
7. Isis Announces Award of Up to $8.4 Million in New Government Grants and Contracts to Its Ibis Biosciences Subsidiary for Pathogen Detection and Human Forensics
8. Pigs bred with cystic fibrosis provide model to mimic human disease
9. Histogen Launches BioNuesis, the Only All-Human Stem Cell Culturing Kit
10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at UBS Conference
11. China Biologic Receives SFDA Approval for Clinical Trial of Human Coagulation Factor VIII
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... August 22, 2014 “Our nation's ... is a national disgrace. Furthermore, every governmental and ... the current, deplorable state of unorganized dysfunction shares ... mistakes," to merely serve as a device to ... of colossal failure(s) that have accumulated through the ...
(Date:8/21/2014)... 2014 Deep Research Report ... professional and in-depth research report on the ... Seaweed Fertilizer information, including Seaweed Fertilizer definition, ... well as industry overview. This research covers ... as well as global industry analysis covering ...
(Date:8/21/2014)... Mass. , Aug. 21, 2014  Decision ... Brazil and ... The uptake of several newly approved agents, the ... this indication and the launch of emerging biologics ... markets. In particular, the emerging IL-5 inhibitors will ...
(Date:8/21/2014)... August 21, 2014 Pursuit Solutions ... optimization technology and services for Life Sciences sales ... Pharma’s Use of New Commercial Sales Models” by ... Analytics. , The article examines some innovative models ... are being tested in the pharmaceutical market. Robinson ...
Breaking Biology Technology:5 Great Mistakes in Healthcare and How to Fix Them by Dr. Ira Williams 2Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 2Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 3Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 2Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 3Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2
... a carbon lattice with a honeycomb structure, has great ... electronic devices. But applications have been stymied because the ... not function effectively as a semiconductor to amplify or ... sheets into nanoscale ribbons can open up a larger ...
... , ... ... ... ...
... , ... ... ... ...
Cached Biology Technology:New graphene 'nanomesh' could change the future of electronics 2Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease 2Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease 3Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease 4Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease 5Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease 6Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease 7Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease 8Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease 9Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease 10Fate Therapeutics Named One of the 50 Most Innovative Companies in the World by MIT's Technology Review 2Fate Therapeutics Named One of the 50 Most Innovative Companies in the World by MIT's Technology Review 3Fate Therapeutics Named One of the 50 Most Innovative Companies in the World by MIT's Technology Review 4Fate Therapeutics Named One of the 50 Most Innovative Companies in the World by MIT's Technology Review 5Fate Therapeutics Named One of the 50 Most Innovative Companies in the World by MIT's Technology Review 6
(Date:8/22/2014)... (Edmonton) Thanks to important discoveries in basic and ... cancer has mobilized into a complex offensive spanning ... of Alberta chemistry lab could help find new ... developed a compound that targets a specific enzyme ... activity in cells from brain tumours. , Chemistry ...
(Date:8/22/2014)... Green tea polyphenols are strong antioxidants and ... protect spinal cord neurons against oxidative stress? ... Affiliated Hospital of Liaoning Medical University, China ... oxidative stress and inhibit neuronal apoptosis, indicating ... in spinal cord neurons under oxidative stress. ...
(Date:8/22/2014)... birds and the bees. But that old expression ... The fertilization process for flowering plants is particularly ... and female reproductive cells. New research from an ... and including Carnegie,s Wolf Frommer, David Ehrhardt, and ... process that guides flowering plant fertilization. It is ...
Breaking Biology News(10 mins):New enzyme targets for selective cancer therapies 2New enzyme targets for selective cancer therapies 3Calcium and reproduction go together 2
... cancer screening tests are proven to reduce colorectal cancer mortality, ... older receive the recommended tests, according to a report in ... Prevention , a journal of the American Association for Cancer ... conducted a National Health Interview Survey and found only 50 ...
... Using an engineered common cold virus, UCLA researchers delivered ... them, using Positron Emission Tomography (PET), to locate the ... the first place prostate cancer goes before invading other ... lymph nodes are very difficult to find using conventional ...
... probably one of the most commonly used diagnostics in ... the throat while the patient says, "Aaaah". But, research ... Journal of Medical Engineering and Informatics looks set ... The technique could circumvent the problem of the failing ...
Cached Biology News:Colorectal cancer screening rates still too low 2UCLA researchers locate and image prostate cancer as it spreads to lymph nodes 2UCLA researchers locate and image prostate cancer as it spreads to lymph nodes 3Sounding out heart problems automatically 2
Immunogen: Synthetic peptide (aa sequence is considered to be commercially sensitive) Storage: -20 C, Avoid Freeze/Thaw Cycles...
For use with SSP products or any application requiring agarose gel separation • Multiple formats available to meet various throughput needs • Includes replacement parts for each un...
recombination at attR1 and attR2 sites...
...
Biology Products: